Krystal Biotech (FRA:4KB) Interest Expense : €0.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Krystal Biotech Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Krystal Biotech's interest expense for the three months ended in Dec. 2024 was € 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was €0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Krystal Biotech's Operating Income for the three months ended in Dec. 2024 was € 39.5 Mil. Krystal Biotech's Interest Expense for the three months ended in Dec. 2024 was € 0.0 Mil. GuruFocus does not calculate Krystal Biotech's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Krystal Biotech Interest Expense Historical Data

The historical data trend for Krystal Biotech's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Krystal Biotech Interest Expense Chart

Krystal Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-1.32

Krystal Biotech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Krystal Biotech Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Krystal Biotech (FRA:4KB) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Krystal Biotech's Interest Expense for the three months ended in Dec. 2024 was €0.0 Mil. Its Operating Income for the three months ended in Dec. 2024 was €39.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was €5.8 Mil.

Krystal Biotech's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate Krystal Biotech's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Krystal Biotech Inc has enough cash to cover all of its debt. Its financial situation is stable.

Krystal Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (FRA:4KB) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

KRYS:USA 4KB:Germany

Address

2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203

Website

https://www.krystalbio.com

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Krystal Biotech Headlines

No Headlines